Literature DB >> 4019276

Strategies for treating possible tumor extension: some theoretical considerations.

M Goitein, T E Schultheiss.   

Abstract

When there is a small possibility of cancer having extended to a region some distance from the main bulk of disease, it may be unclear whether to include that region in the target volume and, if so, what dose should be delivered to it. We have constructed a theoretical model that includes dose and volume relationships for both diseased and normal tissue. With this model one can calculate the change in tumor control probability (TCP) when varying doses are delivered to the regions of known and suspected disease. Values of TCP as a function of dose to the region of suspected disease have been calculated for a wide range of the variables on which the model depends. We conclude that the strategy of treating the region of suspected disease to about 70% of the dose delivered to the region of known disease is almost always better than not treating it at all, or treating both regions to a uniform but reduced dose designed to keep the probability of complication the same. The gain in TCP could be from 5 to 15% for situations of clinical interest.

Entities:  

Mesh:

Year:  1985        PMID: 4019276     DOI: 10.1016/0360-3016(85)90341-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Ranking radiotherapy treatment plans using decision-analytic and heuristic techniques.

Authors:  N L Jain; M G Kahn
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1991

2.  Determination and comparison of radiotherapy dose responses for hepatocellular carcinoma and metastatic colorectal liver tumours.

Authors:  A Lausch; K Sinclair; M Lock; B Fisher; N Jensen; S Gaede; J Chen; E Wong
Journal:  Br J Radiol       Date:  2013-05-20       Impact factor: 3.039

3.  Impact of potentially variable RBE in liver proton therapy.

Authors:  Yizheng Chen; Clemens Grassberger; Junli Li; Theodore S Hong; Harald Paganetti
Journal:  Phys Med Biol       Date:  2018-09-21       Impact factor: 3.609

4.  Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.

Authors:  Michelle A Stinauer; Brian D Kavanagh; Tracey E Schefter; Rene Gonzalez; Thomas Flaig; Karl Lewis; William Robinson; Mark Chidel; Michael Glode; David Raben
Journal:  Radiat Oncol       Date:  2011-04-08       Impact factor: 3.481

5.  High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.

Authors:  Won Il Jang; Mi-Sook Kim; Sun Hyun Bae; Chul Koo Cho; Hyung Jun Yoo; Young Seok Seo; Jin-Kyu Kang; So Young Kim; Dong Han Lee; Chul Ju Han; Jin Kim; Su Cheol Park; Sang Bum Kim; Eung-Ho Cho; Young Han Kim
Journal:  Radiat Oncol       Date:  2013-10-27       Impact factor: 3.481

6.  Analysis of Hepatocellular Carcinoma Stereotactic Body Radiation Therapy Dose Prescription Method Using Uncomplicated Tumor Control Probability Model.

Authors:  Michael L M Cheung; Monica W K Kan; Vanessa T Y Yeung; Darren M C Poon; Michael K M Kam; Louis K Y Lee; Anthony T C Chan
Journal:  Adv Radiat Oncol       Date:  2021-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.